CCR7 and breast carcinoma: Lenalidomide treated XBP1-CTL showed a distinctive cell proliferation pattern, while was restricted mainly to the central memory (CD45RO+CCR7+) CD3+CD8+ T cell subset, in response to the respective solid tumor cells including HLA-A2+ breast cancer (MDA-MB231; 89% CM proliferation), colon cancer (SW480; 92% CM proliferation) or pancreatic cancer (Panc1; 93% CM proliferation) cells (Figure 5A).